If successful, the company believes its affordable option could revolutionize EV adoption levels in America.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A bevy of results from fast food companies last week showed that chicken still reigns supreme over American taste buds.
Vegas has been dealing with the economic uncertainty caused by the Trump administration’s trade, tariff and immigration policies.
Just a week after Figma’s successful market debut, Firefly Aerospace saw its stock pop more than 34% after listing on the Nasdaq on Thursday.
Lilly’s second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.
Revenue from theme parks in the US rose 10% to $6.4 billion, with passenger cruises and resort stays registering higher turnout.
Uber users in Atlanta and Austin can already use the ride-hailing app to order robotaxis from Alphabet subsidiary Waymo.
Russia and China have already announced plans for a joint-base small modular nuclear react on the moon by the mid-2030s.
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.
During the company’s second-quarter earnings report last month, Musk admitted the company may be headed for “a few rough quarters.”
Warner Bros. Discovery entered the year stuck in media conglomerate mud, with its eponymous film studio in especially bad shape.
The AI-powered, data-crunching defense tech company enters its earnings call Monday as the year’s hottest stocks on the S&P 500.
AI is moving into jobs in food services and retail traditionally best left to humans. Can the imperfect tech give customers what they want?
Rather than jockeying for an advantage in their weakened state, the two longtime rivals are set to work together more and more.
The company, mired in too many scandals and setbacks to print, lost nearly $12 billion when all was said and done in 2024.
Staffing shortages, rising prescription drug use, and costly new therapies have driven inflation in the medical sector.